Drug data last refreshed 16h ago · AI intelligence enriched 1w ago
SANCTURA is an oral small-molecule tablet approved in 2004 for an unknown indication via NDA. The mechanism of action and pharmacologic class are not specified in available data.
Product approaching loss of exclusivity signals a contracting brand team; positions are likely focused on transition planning rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial
Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily
Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial
SANCTURA currently shows zero linked job openings, reflecting its mature, declining lifecycle stage. Career opportunities on this product are minimal; professionals should expect either role consolidation or redeployment to growth-stage brands within AbbVie's portfolio.
Worked on SANCTURA at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.